BrainStorm Cell Therapeutics Shares Fall After Updated Biomarker Data From Lead Cell Therapy Candidate
Portfolio Pulse from Vandana Singh
BrainStorm Cell Therapeutics Inc (NASDAQ:BCLI) presented new biomarker data from the Phase 3 trial of its ALS treatment, NurOwn, showing significant elevation in markers of neuroprotection and reduction in markers of neuroinflammation and neurodegeneration. Statistical modeling identified three biomarkers that predict clinical outcomes with NurOwn treatment. Despite this, BCLI shares fell by 4.50% in the premarket session.
July 07, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Despite promising Phase 3 trial data for its ALS treatment, NurOwn, BrainStorm Cell Therapeutics' shares fell by 4.50% in the premarket session.
The new biomarker data from the Phase 3 trial of NurOwn is a positive development for BrainStorm Cell Therapeutics. However, the market reaction was negative, with BCLI shares falling by 4.50% in the premarket session. This could be due to a variety of factors, including market sentiment, overall market conditions, or investor concerns about the company's future prospects.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100